

- Cholecystitis (*Cont.*):
 fasting-induced, 415e-6
 gallbladder cancer and, 553
 treatment of, 2080, 2082
- Cholecystokinin (CCK), 415e-2, 1913f, 2090
- Cholecystokinin (CCK)-releasing factor, 2091
- Cholecystopathy, acalculous, 2081
- Cholecystosis(es), hyperplastic, 2083
- Choledochal cysts, 552, 2083
- Choledocholithiasis, **2083**
 in cholangiocarcinoma, 552
 clinical features of, 285, 2083
 complications of, 2083–2084
 diagnosis of, 2084, 2085t
 pathophysiology of, 2083
 treatment of, 2084
- Cholelithiasis. *See* Gallstone(s)
- Cholera, **1061**
 clinical features of, 266t, 856t, **1063**, 1063f
 diagnosis of, 1063
 differential diagnosis of, 266t, 856t
 epidemiology of
 climate change and, 151e-8, 151e-8f
 environmental factors, 1061
 genomics in, 777, 777f
 historical studies, 776
 global considerations in, 1061–1062, 1062f
 pancreatic, 269
 pathogenesis of, 856t, 1062–1063. *See also* *Vibrio cholerae*
 prevention of, 1064–1065. *See also* Cholera vaccine
 treatment of, 1063–1064, 1064t
- Cholera gravis, 1061, 1063
- Cholera vaccine
 killed whole-cell, 1064–1065
 live attenuated viral, 1065
 for travelers, 795, 795t
- Cholestasis
 benign postoperative, 284
 benign recurrent intrahepatic, 284, 2003t, 2004, 2076
 drug-induced, 284, 2023, 2025, 2025t, 2026t, 2030
 extrahepatic, 283, 284t, 285
 imaging in, 283–284
 intrahepatic, 284, 284t
 jaundice in, 283–285
 in lipoprotein disorders, 2443
 liver function tests in, 1997, 1998t
 parental nutrition and, 2030
 of pregnancy, 49, 284, 2029, 2078
 progressive familial intrahepatic, 284, 2003t, 2004
- Cholestatic diseases, 1990, 1990t. *See also* Liver disease/failure
- Cholesteatoma, 218, 230
- Cholesterol, reverse transport of, 291e-2
- Cholesterol absorption inhibitors, 2448–2449, 2448t
- Cholesterol embolism
 in kidney, 62e-9f, 1835t, 1848
 retinal, 40e-4
 skin manifestations of, 368
- Cholesterolemia, 2083
- Cholesterol side-chain cleavage enzyme (CYP11a), 372e-24t
- Cholesterol stones
 gallbladder, 2076–2077, 2077f, 2078t. *See also* Gallstone(s)
 in short bowel syndrome, 1943
- Cholesteryl ester storage disease (CESD), 432e-4t, 432e-5, 2443
- Cholesteryl ester transfer protein (CETP), 2438, 2438f
- Cholesteryl ester transfer protein (CETP) deficiency, 2446
- Cholesteryl ester transfer protein (CETP) inhibitors, 291e-6
- Cholestyramine
 adverse effects of, 269, 2448t
 drug interactions of, 42t
 for irritable bowel syndrome, 1970t
 for lipoprotein disorders, 2448t, 2449
 for metabolic syndrome, 2453
 for pruritus, 2086
 vitamin A absorption and, 96e-6
- Cholic acid, 2076
- Choline, 95e-2t, **96e-5**
- Cholinergic urticaria, 363, 363t, 2118, 2119
- Cholinesterase inhibitors
 for AD, 2601
 adverse effects of, 2601, 2704
 for dementia, 176
 for dementia with Lewy bodies, 2606
 for myasthenia gravis, 2704
- Chondritis, 166e-2, 2203, 2203f
- Chondrocalcinosis, 306, 2235
- Chondrocyte(s), 2227, 2227f, 2233
- Chondrodysplasia(s), **2511**
 classification of, 2511
 diagnosis of, 2512
 genetic considerations in, 2511–2512
 incidence of, 2511
 treatment of, 2512
- Chondrodysplasia punctata, fetal, 47
- Chondroitin, 2232
- Chondromatosis, synovial, 2246–2247
- Chondrosarcoma, 101e-6f, **119e-3**
- Choose My Plate, 95e-5, 95e-6t
- CHOP regimen, 705–706
- Chordoma, 119e-3, 2264
- Chorea(s), **2621**
 clinical features of, 2619t
 disorders associated with, 2622–2623
 Huntington's disease. *See* Huntington's disease
 paraneoplastic, 614t
 Sydenham's, 49, 377e-1, 2151, 2622
 treatment of, 2153
- Chorea-acanthocytosis, 2622
- Chorea gravidarum, 49
- Choriocarcinoma. *See also* Gestational trophoblastic disease
 incidence of, 124e-5
 ovarian, 594–595
 paraneoplastic syndromes in, 609t
 parasellar, 2264
 testicular, 588
- Choriomeningitis, lymphocytic, 837, 908t
- Chorionic villus sampling (CVS), 83e-3–4, 444
- Chorioretinopathy, central serous, 205–206
- Choroid, 40e-1
 gyrate atrophy of, 434e-3t
 mass lesions of, 40e-5–6, 40e-5f
 melanoma of, 206, 206f
- Choroidal artery, occlusion of, 2573–2574, 2575f
- CHRNA4 gene mutations, 2545t
- Chromatin
 in cancer cells, 102e-7–8, 102e-8f, 103e-6
 in DNA, 427, 427f
- Chromatin immunoprecipitation, 455
- Chromium, **96e-10**
 carcinogenicity of, 96e-10, 472e-3, 506
 deficiency of, 96e-9t
 dietary sources of, 96e-10
 functions of, 96e-10
 parental supplementation of, 98e-6t
 recommended intake of, 95e-3t
 supplements, 96e-10
 tolerable upper intake level of, 96e-9t
 toxicity of, 96e-9t, 477t
- Chromobacterium violaceum*, 183e-3
- Chromoblastomycosis, 1355
- Chromogranin
 in carcinoma of unknown primary, 120e-2t, 120e-4
 in GI-NETs, 566
 in lung cancer, 507, 508
 in nonfunctional pNETs, 571
- Chromophobe tumors, renal, 578, 578t
- Chromophores, 386
- Chromosomal instability, 101e-3–4, 101e-5. *See also* Cancer genetics
- Chromosomal mosaicism, 439
- Chromosomal sex, 2349, 2349f
- Chromosome(s)
 acrocentric, 83e-5
 analysis of. *See* Cytogenetic analysis;
 Cytogenomic analysis
 crossing-over and recombination of, 428, 430f
 imprinting in, 430, 432f
 replication of, 426
 staining techniques for, 83e-1
 structure of, 426, 427f
- Chromosome abnormalities/disorders, **83e-1**.
See also Genetic disorders; *specific diseases*
 in cancer, 83e-7, 101e-3t
 contiguous gene syndromes, 432, 437
 copy number variations, 427, 430f
 deletions, 83e-6, 434
 duplications, 83e-6
 imprinting, 83e-7
 insertions, 434
 inversions, 83e-6
 numerical, 83e-1, 83e-4–5
 in radiation-exposed patient, 263e-7
 in sex chromosomes, 2350t. *See also* Disorders of sex development (DSDs)
 single-nucleotide polymorphisms. *See* Single-nucleotide polymorphisms (SNPs)
 structural, 83e-1, 83e-5–7, 83e-5f
 translocation. *See* Translocation, chromosome
 unequal crossing-over, 434
 uniparental disomy, 83e-6–7, 83e-6f
- Chromosome banding, 83e-1
- Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE), 2215
- Chronic beryllium disease/toxicity, 367, 373e-7, 1691
- Chronic bronchitis, 244, 1692t, 1701
- Chronic Care Model, 12e-3, 12e-3f
- Chronic disease–related malnutrition. *See* Cachexia (chronic disease–related malnutrition)
- Chronic eosinophilic leukemia, 135e-7–8, 135e-7t, 422, 672
- Chronic fatigue syndrome, **464e-1**
 clinical features of, 464e-1, 2199
 definition of, 464e-1
 diagnosis of, 464e-1t, 464e-2, 464e-2f
 EBV infection and, 1188
 epidemiology of, 464e-1
 etiology of, 464e-1, 464e-1t
 vs. Lyme disease, 1152
 pathophysiology of, 464e-1–2
 prognosis of, 464e-3
 treatment of, 464e-2–3
- Chronic granulomatous diseases (CGDs)
 cellular/molecular defects in, 419, 419t, 421, 2106
 clinical features of, 419t, 421, 2106
 complications of, 421
 diagnosis of, 419t
 treatment of, 372e-30, 423, 2106
 X-linked, 375e-1, 2106
- Chronic infantile neurologic cutaneous and articular syndrome (CINCA), 372e-8t
- Chronic inflammatory demyelinating polyneuropathy (CIDP), 2696t, **2698**
- Chronic kidney disease (CKD), **1811**
 in amyloidosis, 719, 721. *See also* Amyloidosis
 approach to the patient
 establishment of diagnosis and etiology, 1820
 history and physical examination, 1819
 imaging, 1820
 laboratory studies, 1813, 1813t, 1819–1820, 2768–2769t
 renal biopsy, 1820
 staging, 1812–1813
 calcium and phosphate metabolism disorders in
 bone manifestations of, 1815
 calciphylaxis, 1816, 1816f
 cardiovascular manifestations of, 1815
 hyperphosphatemia, 2460, 2485
 hypocalcemia, 333e-3, 462e-19, 2484–2485